Drug Trial Radar · NCT03093116
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Last checked: Nov 19, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Mar 7, 2017
Primary completion
Feb 29, 2028
Study completion Feb 29, 2028
Sponsor
- Lead sponsor
- Turning Point Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Zai Lab (Shanghai) Co., Ltd.
- First posted
- Mar 28, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
Conditions
- Locally Advanced Solid Tumors
- Metastatic Solid Tumors
Interventions
Oral repotrectinib (TPX-0005)Drug
Oral repotrectinib (TPX-0005) capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicities (DLTs) (Phase 1)Time frame: Within 28 days of the first repotrectinib dose
- Recommended Phase 2 Dose (RP2D) (Phase 1)Time frame: Within 28 days of the last patient dosed in escalation
- Overall Response Rate (ORR) Phase 2Time frame: Two to three years after first dose of repotrectinib dose
Locations
165 sites in 19 countries. Site status is shown where the registry gives one.
Local Institution - 2129
Duarte, California · Completed
Local Institution - 2120
Glendale, California · Completed
Local Institution - 2136
La Jolla, California · Withdrawn
Local Institution - 2114
La Jolla, California · Completed
Local Institution - 2121
Long Beach, California · Completed
Local Institution - 1001
Orange, California · Completed
Local Institution - 2101
Orange, California · Completed
St Joseph Heritage Healthcare
Santa Rosa, California · Recruiting
Local Institution - 1003
Aurora, Colorado · Completed
Local Institution - 2103
Aurora, Colorado · Completed
Local Institution - 2106
Washington D.C., District of Columbia · Completed
Local Institution - 2110
Washington D.C., District of Columbia · Completed
Memorial Healthcare System
Hollywood, Florida · Recruiting
Local Institution - 2113
Tampa, Florida · Completed
University Cancer and Blood Center
Athens, Georgia · Recruiting
Local Institution - 2134
Columbus, Georgia · Completed
University of Chicago
Chicago, Illinois · Recruiting
Local Institution - 2142
Peoria, Illinois · Completed
Local Institution - 2116
New Orleans, Louisiana · Not yet recruiting
Local Institution - 2133
Baltimore, Maryland · Completed
Massachusetts General Hospital,
Boston, Massachusetts · Recruiting
Local Institution - 1004
Boston, Massachusetts · Completed
Local Institution - 2131
Boston, Massachusetts · Completed
Local Institution - 2105
Ann Arbor, Michigan · Completed
Local Institution - 2111
Detroit, Michigan · Completed
Local Institution - 2140
Detroit, Michigan · Completed
Local Institution - 2132
Saint Paul, Minnesota · Completed
Local Institution - 2147
Bolivar, Missouri · Completed
Washington University Infusion Center Pharmacy
St Louis, Missouri · Recruiting
Local Institution - 2122
New Brunswick, New Jersey · Completed
Local Institution - 2117
New York, New York · Completed
Local Institution - 1002
New York, New York · Active not recruiting
Local Institution - 2102
New York, New York · Completed
Local Institution - 2144
Goldsboro, North Carolina · Completed
Local Institution - 2112
Canton, Ohio · Completed
Local Institution - 2143
Cincinnati, Ohio · Completed
Local Institution - 2109
Cleveland, Ohio · Completed
The Ohio State University Wexner Medical Center
Columbus, Ohio · Recruiting
Local Institution - 2119
Toledo, Ohio · Completed
Local Institution - 2108
Philadelphia, Pennsylvania · Completed
Showing 40 of 165 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.